Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance?

Journal of the National Cancer Institute

Volumn 95, Issue 19, 2003, Pages 1440-1452

  Choy, Hak ^a   Milas, Luka ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; PACLITAXEL; PIROXICAM; PLACEBO; PREDNISOLONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOSENSITIZING AGENT; SEMAXANIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VATALANIB; ENDOTHELIAL CELL GROWTH FACTOR; ENZYME INHIBITOR; ISOENZYME; LYMPHOKINE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SIGNAL PEPTIDE; SULFONAMIDE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL MODEL; APOPTOSIS; BRAIN CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOGENESIS; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SCREENING; DRUG SELECTIVITY; DRUG USE; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; EXPERIMENTATION; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; METASTASIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STANDARD; TUMOR CELL; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; BIOSYNTHESIS; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); RADIATION EXPOSURE; SURVIVAL; TREATMENT OUTCOME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; LYMPHOKINES; MEMBRANE PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; SULFONAMIDES; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0141540687     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg058     Document Type: Review

References (165)

1. Mirzaie-Joniani H, Eriksson D, Sheikholvaezin A, Johansson A, Lofroth PO, Johansson L, et al. Apoptosis induced by low-dose and low-dose rate radiation. Cancer 2002;94:1210-4.
2. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994;65:27-33.
3. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1997;71:1-25.
4. Wheeler JA, Stephens LC, Tornos, C, Eifel PJ, Ang KK, Milas L, et al. ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1995;32: 1487-93.
5. Akimoto T, Seong J, Hunter NR, Buchmiller L, Mason K, Milas L. Association of increased radiocurability of murine carcinomas with low constitutive expression of p21 (WAF1/CIP1) protein. Int J Radiat Oncol Biol Phys 1999;44:413-9.
6. Bielenberg DR, Bucana CD, Sanchez R, Donawho CK, Kripke ML, Fidler IJ. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol 1998;111:864-72.
7. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
8. Shintani S, Kiyota A, Mihara M, Nakahara Y, Terakado N, Ueyama Y, et al. Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J Cancer Res 2000;91:1051-7.
9. Hellman S. Principles of cancer management: radiation therapy. In: De-Vita VT, Rosenberg S, Hellman S, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia (PA): Lippincott, Williams and Wilkins, 2001:265-88.
10. Rosen EM, Fan S, Goldberg ID, Rockwell S. Biological basis of radiation sensitivity. Part 2: cellular and molecular determinants of radiosensitivity. Oncology (Huntingt) 2000;14:741-57.
11. Rosen EM, Fan S, Goldberg ID, Rockwell S. Biological basis of radiation sensitivity. Part 1: factors governing radiation tolerance. Oncology (Huntingt) 2000;14:543-50.
12. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Porte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063-73.
13. Milas L, Hanson WR. Eicosanoids and radiation. Eur J Cancer 1995;31A: 1580-5.
14. Steinauer KK, Gibbs I, Ning S, French JN, Armstrong J, Knox SJ. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 2000;48:325-8.
15. Michalowski AS. On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs. Acta Oncol 1994;33:139-57.
16. Dubois A, Dorval ED, Steel L, Fiala NP, Conklin JJ. Effect of ionizing radiation on prostaglandins and gastric secretion in rhesus monkeys. Radiat Res 1987; 110:289-93.
17. Donlon M, Steel L, Helgeson EA, Shipp A, Catravas GN. Radiation-induced alterations in prostaglandin excretion in the rat. Life Sci 1983; 32:2631-9.
18. Steel LK, Catravas GN. Radiation-induced changes in production of prostaglandins F2 alpha, E, and thromboxane B2 in guinea pig parenchymal lung tissues. Int J Radiat Biol Relat Stud Phys Chem Med 1982;42: 517-30.
19. Billings PC, Maki PA, Kennedy AR. Effect of modifiers of arachidonic acid metabolism on radiation transformation and eicosanoid formation in C314/10TI/2 cells. Cancer Biochem Biophys 1994;14:211-20.
20. Eisen V, Walker DI. Effect of ionizing radiation on prostaglandin-like activity in tissues. Br J Pharmacol 1976;57:527-32.
21. Eldor A, Vlodavsky I, HyAm E, Atzmon R, Fuks Z. The effect of radiation on prostacyclin (PG12) production by cultured endothelial cells. Prostaglandins 1983;25:263-79.
22. Hahn GL, Menconi MJ, Cahill M, Polgar P. The influence of gamma radiation on arachidonic acid release and prostacyclin synthesis. Prostaglandins 1983;25:783-91.
23. Eisen V, Walker DI. Effect of ionizing radiation on prostaglandin 15-OH-dehydrogenease (PGDH) [proceedings]. Br J Pharmacol 1978;62:461P.
24. Rubin DB, Drab EA, Ts'ao CH, Gardner D, Ward WF. Prostacyclin synthesis in irradiated endothelial cells cultured from bovine aorta. J Appl Physiol 1985;58:592-7.
25. Zaffroni N, Villa R, Orlandi L, De Pascale A, Del Mastro S, Silvestrini R. Differential effect of 9 beta-chloro-16, 16-dimethyl prostaglandin E2 (nocloprost) on the radiation response of human normal fibroblasts and colon adenocarcinoma cells. Radiat Res 1993;135;88-92.
26. Hanson WR, Thomas C. 16, 16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat Res 1983;96:393-8.
27. Tomas-de la Vega JE, Banner BF, Hubbard M, Boston DL, Thomas CW, Straus AK, et al. Cytoprotective effect of prostaglandin E2 in irradiated rat ileum. Surg Gynecol Obstet 1984;158:39-45.
28. Hanson WR, DeLaurentiis K. Comparison of in vivo murine intestinal radiation protection by E-prostaglandins. Prostaglandins 1987;33 Suppl: 93-104.
29. Riehl T, Cohn S, Tessner T, Schloemann S, Stenson WF. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology 2000;118:1106-16.
30. Walden TL Jr, Patchen ML, MacVittie TJ. Leukotriene-induced radioprotection of hematopoietic stem cells in mice. Radiat Res 1988;113: 388-95.
31. Malkinson FD, Geng L, Hanson WR. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. J Invest Dermatol 1993;101:135S-7S.
32. Furuta Y, Hunter N, Barkley T Jr, Hall E, Milas L. Increase in radioresponse of murine tumor by treatment with indomethacin. Cancer Res 1988;48:3008-13.
33. Milas L, Furuta Y, Hunter N, Nishiguchi I, Runkel S. Dependence of indomethacin-included potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res 1990;50:4473-7.
34. Blomgren H, Wasserman J, Rotstein S, Petrini B, Baral E. Possible role of prostaglandin producing monocytes in the depression of mitogenic responses of blood lymphocytes following radiation therapy. Radiother Oncol 1984;1:255-61.
35. Wasserman J, Blomgren H, Rotstein S, Petrini B, Hammarstrom S. Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors. Bull NY Acad Med 1989;65:36-44.
36. Blomgren H, Rotstein S, Wasserman J, Petrini B, Hammarstrom S. In vitro capacity of various cyclooxygenase inhibitors to revert immune suppression caused by radiation therapy for breast cancer. Radiother Oncol 1990;19:329-35.
37. Petrini B, Wolk G, Wasserman J, Vedin I, Strannegard O, Blomgren H, et al. Indomethacin modulation of monocyte cytokine release following pelvic irradiation for cancer. Eur J Cancer 1991;27:591-4.
38. Nishiguchi I, Furuta Y, Hunter N, Murray D, Milas L. Radioprotection of hematopoietic tissues in mice by indomethacin. Radiat Res 1990;122: 188-92.
39. Milas L, Nishiguchi I, Hunter N, Murray D, Fleck R, Ito H, et al. Radiation protection against early and late effects of ionizing irradiation by the prostaglandin inhibitor indomethacin. Adv Space Res 1992;12:265-71.
40. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602-6.
41. Furuta Y, Hall ER, Sanduja S, Barkely T Jr, Milas L. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 1988;48:3002-7.
42. Weppelmann B, Monkemeier D. The influence of prostaglandin antagonists on radiation therapy of carcinoma of the cervix. Gynecol Oncol 1984;17:196-9.
43. Pillsbury HC III, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch Otolaryngol Head Neck Surg 1986;112:552-3.
44. Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol Suppl 1998;51:2-7.
45. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
46. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
47. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
48. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther 1999;21:992-1003.
49. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;23:232-5.
50. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
51. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:23261-7.
52. Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci U S A 1989;86:1178-82.
53. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88: 2692-6.
54. Houchen CW, Stenson WF, Cohn SM. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. Am J Physiol Gastrointest Liver Physiol 2000;279:G858-G865.
55. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28:67-81.
56. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999;96:7563-8.
57. Cohn SM, Schloemann S, Tessner T, Seibert K, Stenson WF. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest 1997;99: 1367-79.
58. Marnett JL. Cyclooxyenase mechansisms. Curr Opin Chem Biol 2000;4: 545-52.
59. Bakhle YS. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001;134:1137-50.
60. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors - current status and future prospects. Eur J Med Chem 2001;36:109-26.
61. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37: 431-502.
62. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002;9:28-35.
63. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5: 138-46.
64. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
65. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
66. Jacoby RF, Seibert K, Cole CE, Kelloff G, Luber RA. The cycooxytenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60;5040-4.
67. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
68. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan K, Masferrer JL, et al. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
69. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97: 1037-41.
70. Eberhart CE, Coffrey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
71. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
72. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-7.
73. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, et al. Upregulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121:1339-47.
74. Uefuji K, Ichikura T, Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001;76: 26-30.
75. Saukkonen K. Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-31.
76. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157:729-35.
77. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122:1800-7.
78. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-6.
79. Zimmerman KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cycloooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
80. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-34.
81. Ratnasinghe D, Tangrea J, Roth MJ, Dawsey S, Hu N, Anver M, et al. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey. Anticancer Res 1999; 19: 171-4.
82. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
83. Merati K, said Siadaty SM, Andea A, Sarkar F, Ben Josef E, Mohammad R, et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001;24:447-52.
84. Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F, et al. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 2002;94:1565-73.
85. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, et al. Immunohistochemical analysis of cycloooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999;26:69-76.
86. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, et al. Increased expression of cyclooxgenase-2 human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-8.
87. Shiota G, Okubo M, Noumi T, Nogucbi N, Oyama K, Takano Y, et. al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999;46:407-12.
88. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001;7:1410-8.
89. Wolf H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human carcinoma. Cancer Res 1998; 58:4997-5001.
90. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58: 3761-4.
91. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5: 1001-5.
92. Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee LS. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002;94:1023-31.
93. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001;21:1291-4.
94. Gupta VK, Jaskowak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002;8:47-54.
95. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61: 8617-23.
96. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127-31.
97. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424-30.
98. Bostrum PJ, Aaltonen V, Soderstrom KO, Uotila P, Laato M. Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cells. Pathology 2001;33:469-74.
99. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 2001; 158:849-53.
100. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-8.
101. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000;157:29-35.
102. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81.
103. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;277:18639-57.
104. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-34.
105. Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002;95:531-9.
106. Ryh HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000;76:320-5.
107. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RPh, Hofmeyr MD, et al. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 2001;86:2243-9.
108. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:1213-7.
109. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelista A, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002;95:801-7.
110. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002;160:893-903.
111. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001;8:31-6.
112. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4.
113. Denkert C, Kobel M, Berger S, Siegert A, Leclerc A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61:303-8.
114. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
115. Yamauchi T, Watanabe M, Hasegawa H, Ishii Y, Endo T, Kabeshima Y, et al. The role of COX-2 expression in colorectal cancer. Proc Am Assoc Cancer Res 2000;41.
116. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-5.
117. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-8.
118. Gee JR, Lee I-L, Fischer SM, Grossman HB, Sabichi AI. COX-2 selective inhibitor celecoxib induces growth inhibition and apoptosis in bladder Carcinoma. Proc Am Assoc Cancer Res 2002;43:643-4.
119. Zweifel B, Omberg R, Woerner M, Koki A, Masferrer J, Dannenberg A, et al. Inhibition of prostaglandins by celecoxib results in suppression of tumor growth and reduces VEGF levels in human head and neck xenograft model. Proc Am Assoc Cancer Res 2001;43:77.
120. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
121. Folkman J. Tumor angiogenesis. In: Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, editors. Cancer medicine. 5th ed. London: BC Decker Inc., 2002;132-52.
122. Liu XH, Kirshenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-stimulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999;17:687-94.
123. Tsujii M, Kawano S, Tsuji, S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
124. Ben Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
125. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94.
126. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
127. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-77.
128. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-5.
129. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001;93:497-506.
130. Ding I, Liu W, Hu D, Fenton B, Beer D, Okunieff P. Celecoxib inhibits radiation angiogenic growth factor and cytokine mRNA expression in esophageal carcinoma. Proc Am Assoc Cancer Res 2002;43:483.
131. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62:625-31.
132. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett U. Thromboxane A2 is a mediator of cyclooxygenase-2 dependent endothelial migration and angiogenesis. Cancer Res 1999;59:4574-7.
133. Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999;91:1501-4.
134. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326-31.
135. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000;6:2513-20.
136. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001;7:2998-3005.
137. Gaffney DK, Holden J, Zempolich K, Murphy KJ, Dicker AP, Dodson M. Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am J Clin Oncol 2001;24:443-6.
138. Formenti SC, Spicer D, Skinner K, Cohen D, Corso F, Bettini A, et al. Pre-operative twice weekly paclitaxel and radiation therapy in locally advanced breast cancer (LABC): molecular determinants of pathological response. Proc ASCO 1999;18:75a.
139. Fenton BM, Beauchamp BK, Paoni SF, Okunieff P, Ding I. Characterization of the effects of antiangiogenic agents on tumor pathophysiology. Am J Clin Oncol 2001;24:453-7.
140. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000;36:664-74.
141. Hanson D, DeLeo V. Long-wave ultraviolet light induces phospholipase activation in cultured human epidermal keratinocytes. J Invest Dermatol 1990;95:158-63.
142. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;198: 732-9.
143. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002;54:886-94.
144. Han JA, Kim J-I, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, et al. p53-mediated induction of COX-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 2002;21:5635-44.
145. Leung KH, Mihich E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature 1980;288:597-600.
146. Fulton AM, Levy JG. The possible role of prostaglandins in mediating immune suppression by nonspecific T suppressor cells. Cell Immunol 1980;52:29-37.
147. Kambayashi T, Alexander HR, Fong M, Strassmann G. Potential involvement of IL-10 in suppression tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 1995:154:3383-90.
148. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
149. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164: 361-70.
150. Ting LL, Belfi CA, Tefft M, Ngo FQ. KHT sarcoma perfusion change after single-dose X-ray irradiation. Int J Radiat Biol 1991;60:335-9.
151. Kallman RF, DeNardo GL, Stasch MJ. Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res 1972; 32:483-90.
152. Hilmas DE, Gillette EL. Microvasculature of C3H/Bi mouse mammary tumors after x-irradiation. Radiat Res 1975;61:128-43.
153. Johnson R. A thermodynamic method for investigation of radiation induced changes in the microcirculation of human tumors. Int J Radiat Oncol Biol Phys 1976;1:659-70.
154. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka. H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61:2413-9.
155. Taghian A, Ramsay J, Allanlums-Turner J, Budach W, Gioioso D, Pardo F, et al. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1993;25:243-9.
156. Gorksi DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-9.
157. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-91.
158. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000;6:971-8.
159. Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001;85:2010-6.
160. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002;157:45-51.
161. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002;62: 1702-6.
162. Carbone D, Dhoy H, Cisiki T, Dang N, Campbell B, Garcia J, et al. Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in stage III non-small cell lung cancer (NSCL): preliminary results of a phase II trial (THO-0059). Proc ASCO 2002;21:318a.
163. Liao ZX, Chen Y, Komaki R, Cox JD, Milas L. A phase I study combining thoracic radiation (RT) with celecoxib in patients with non-small cell lung cancer (NSCLC). Proc ASCO 2003;22:216.
164. Mantravadi RVP, Fineberg N, Ansari R, Fox E, Helft P, Kesler K, et al. A phase II study of cisplatin, 5-fluorouracil (5-FUO, radiation (RT) and celecoxib in patients with resectable esophageal cancer (EC): preliminary results from the Hoosier oncology Group (HOG). Proc ASCO 2003;22: 291.
165. Pannullo S, Serventi JV, Balmaceda C, Burton J. Proc ASCO 2003;22: 114.